What are Mission Vision & Core Values of Regeneron Pharmaceuticals Company?

The statement is concise yet powerful. It highlights the use of science as the primary driver, the development of new medicines as the product, and the focus on patients with serious diseases as the ultimate beneficiaries. The phrase "over and over again" underscores Regeneron's dedication to continuous innovation.

This Regeneron Mission is strongly innovation-focused. It emphasizes the company's commitment to addressing unmet medical needs through scientific discovery. This commitment is evident in their substantial investments in research and development.

The mission statement is inherently patient-centric. The focus on "people with serious diseases" underscores Regeneron's dedication to improving patient outcomes. This patient-focused approach is a key aspect of their Company Values.

In 2024, Regeneron's investment in research and development exceeded $4.4 billion. This significant financial commitment demonstrates the company's adherence to its mission. This investment fuels the creation of new medicines.

Regeneron's broad clinical pipeline, with approximately 40 investigational candidates covering dozens of disease states, is a clear example of their mission in action. This pipeline reflects their commitment to continuous innovation.

Regulatory approvals, such as Dupixent's approvals for chronic spontaneous urticaria in the U.S. and chronic obstructive pulmonary disease in Japan in early 2025, showcase Regeneron's commitment to bringing new treatments to patients globally. This highlights their Corporate Philosophy.

Regeneron's vision is deeply rooted in scientific innovation. Their investments in cutting-edge technologies, such as VelociSuite® and the Regeneron Genetics Center®, underscore a commitment to data-driven insights and genetic medicine. This focus positions Regeneron to shape the future of medicine.

The ambitious goal of developing approximately 40 investigational medicines by 2025 reflects a vision of significantly broadening their therapeutic reach. This expansion aims to address a wider array of serious diseases, impacting the lives of more patients. This is a key component of the Regeneron Mission.

Regeneron's substantial investments in infrastructure and manufacturing, exceeding $7 billion in New York and North Carolina, demonstrate a vision of sustained growth. These expansions are designed to increase production capacity and ensure the availability of their medicines to a growing patient population.

The company's robust financial performance, with $14.20 billion in total revenues for 2024 (an 8% increase from the previous year), fuels its vision. This financial strength provides the resources necessary to invest in research, development, and expansion, furthering their goals.

A core aspect of Regeneron's vision is its patient-focused approach. This commitment is evident in their research and development efforts, which prioritize addressing unmet medical needs and improving patient outcomes. Their Company Values strongly reflect this.

Regeneron's vision extends beyond simply developing medicines; it encompasses shaping the future of healthcare. Their investments in technology, research, and manufacturing are all geared towards creating a healthier future. To understand their target audience, consider reading this article: Target Market of Regeneron Pharmaceuticals.

Strategic partnerships and acquisitions are carefully chosen to support the Regeneron Vision of advancing scientific breakthroughs and expanding its therapeutic reach. These moves are guided by the company's core values.

Regeneron's targeted approach to disease areas, such as eye diseases, allergic and inflammatory conditions, and cancer, is a direct reflection of its patient-focused approach and commitment to addressing significant unmet medical needs.

The success of key products demonstrates the tangible impact of their mission-driven R&D efforts, providing clear examples of Regeneron's mission in action and its influence on healthcare. These products are improving the lives of patients worldwide.

Regeneron's commitment to corporate responsibility and sustainable practices, including its inclusion in the Dow Jones Sustainability World Index, reflects its philosophy of 'Doing Well by Doing Good,' which is intertwined with their mission and values.

The positive financial performance of key products, such as Dupixent and EYLEA HD, directly reflects the success of Regeneron's mission-driven strategy. For instance, Dupixent's global net sales increased by 19% in Q1 2025, while EYLEA HD's U.S. net sales grew by 54% in the same period.

Leonard S. Schleifer, M.D., Ph.D., CEO of Regeneron, emphasizes that the company's approach to corporate responsibility is deeply rooted in its Company Values and mission, ensuring a cohesive and values-driven organizational culture.

Leadership plays a critical role in embedding Regeneron's Regeneron Core Values throughout the organization. The CEO, Leonard S. Schleifer, has consistently emphasized the importance of grounding corporate responsibility in the company's values and mission.

Regeneron communicates its Regeneron Mission, Regeneron Vision, and Company Values through multiple channels. This ensures consistent messaging and reinforces the company's commitment to its stakeholders.

Regeneron demonstrates its values in practice through various initiatives that align with its Corporate Philosophy. These actions showcase the company's commitment to improving lives and building sustainable communities.

Regeneron's participation in sustainability programs and its high ranking in ESG ratings further demonstrate its commitment to its values. These initiatives reflect the company's dedication to responsible business practices and its long-term vision.